Venlafaxine extended release (XR) in the treatment of panic disorder
نویسندگان
چکیده
Panic disorder is a chronic, recurrent illness, with a lifetime prevalence of about 5%. It is associated with substantial functional impairment, and studies suggest that treatment with medication alone (and no instruction in exposure to feared and avoided situations) is less than optimal. In fact, 40%-90% of patients in long-term follow-up studies in the late 1980s and early 1990s, treated with antidepressants or high potency benzodiazepines alone, remained somewhat symptomatic. Venlafaxine extended release (XR) was effective and well tolerated in both the short-term and long-term treatment of panic disorder. In 12-week trials, venlafaxine XR was significantly more effective than placebo in achieving a panic-free state (54%-70% vs 34%-48%, p</=0.05), and was as effective as paroxetine. In addition, venlafaxine XR has been shown to produce significantly higher response and remission rates than placebo. Relapse rates were significantly reduced with ongoing venlafaxine XR treatment compared to switching to placebo (22% vs 50%, p</=0.001), in a 6 month study. Importantly, venlafaxine XR significantly improved patient quality of life and functioning, and was generally well tolerated.
منابع مشابه
Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
CONTEXT Generalized anxiety disorder (GAD) is a chronic disorder in need of reliable data to guide long-term treatment. OBJECTIVES To assess the benefits of 6 and 12 months' treatment of GAD with venlafaxine hydrochloride extended release (XR) in patients who improved after 6 months' open-label venlafaxine XR treatment. DESIGN After 6 months' open-label venlafaxine XR treatment, improved pa...
متن کاملVenlafaxine in the treatment of panic disorder
Venlafaxine XR is a novel, dual acting SNRI antidepressant, which inhibits both serotonin and norepinephrine reuptake. Controlled trials have demonstrated the efficacy and safety of venlafaxine in the treatment of panic disorder. Generally well tolerated, with side-effects that usually abate with continued treatment, venlafaxine is an important option to the SSRIs for the treatment of patients ...
متن کاملLong-term goals in the management of acute and chronic anxiety disorders.
Many anxiety disorders are not treated to remission (symptom-free state); however, this should be the minimum goal of therapy. Antidepressant therapies have shown significant beneficial effects in the management of anxiety disorders, with some variability in results in specific disorders. In social anxiety disorder, selective serotonin reuptake inhibitors and venlafaxine extended release (XR) h...
متن کاملVenlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.
BACKGROUND Venlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder. AIMS To evaluate the efficacy, safety and tolerability of venlafaxine ER in treating panic disorder. METHOD Adult out-patients (n=361) with panic disorder were randomly assigned to receive venlafaxine ER (75-225 ...
متن کاملTreatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
BACKGROUND Duloxetine and venlafaxine extended release (venlafaxine XR) are SNRIs indicated for the treatment of MDD. This study addresses whether duloxetine and venlafaxine XR are interchangeable in their patterns of use with patients who are depressed or are used more selectively based on treatment history, background characteristics, and presenting symptoms. METHODS This was a retrospectiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Therapeutics and Clinical Risk Management
دوره 3 شماره
صفحات -
تاریخ انتشار 2007